Demonstration of Nucleoside Transporter Activity in the Nose-to-Brain Distribution of [18F]Fluorothymidine Using PET Imaging
To evaluate the role of nucleoside transporters in the nose-to-brain uptake of [18F]fluorothymidine (FLT), an equilibrative nucleoside transporter (ENT1,2) and concentrative nucleoside transporter (CNT1–3) substrate, using PET to measure local tissue concentrations. Anesthetized Sprague-Dawley rats were administered FLT by intranasal (IN) instillation or tail-vein injection (IV). NBMPR (nitrobenzylmercaptopurine riboside), an ENT1 inhibitor, was administered either IN or intraperitoneally (IP). Dynamic PET imaging was performed for up to 40 min. A CT was obtained for anatomical co-registration and attenuation correction. Time-activity curves (TACs) were generated for the olfactory bulb (OB) and remaining brain, and the area-under-the-curve (AUC) for each TAC was calculated to determine the total tissue exposure of FLT. FLT concentrations were higher in the OB than in the rest of the brain following IN administration. IP administration of NBMPR resulted in increased OB and brain FLT exposure following both IN and IV administration, suggesting that NBMPR decreases the clearance rate of FLT from the brain. When FLT and NBMPR were co-administered IN, there was a decrease in the OB AUC while an increase in the brain AUC was observed. The decrease in OB exposure was likely the result of inhibition of ENT1 uptake activity in the nose-to-brain transport pathway. FLT distribution patterns show that nucleoside transporters, including ENT1, play a key role in the distribution of transporter substrates between the nasal cavity and the brain via the OB.
KEY WORDSIntranasal administration Nucleoside transporters [18F]fluorothymidine ENT1 CNT3 Nose-to-brain transport
Research reported in this publication was supported by the National Institute on Deafness and Other Communication Disorders of the National Institutes of Health under award number R01DC008374-03S1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
- 3.Shingaki T, Hidalgo IJ, Furubayashi T, Katsumi H, Sakane T, Yamamoto A, et al. The transnasal delivery of 5-fluorouracil to the rat brain is enhanced by acetazolamide (the inhibitor of the secretion of cerebrospinal fluid). Int J Pharm. 2009;377(1):85–91. https://doi.org/10.1016/j.ijpharm.2009.05.009.CrossRefPubMedGoogle Scholar
- 9.Al-Ghabeish M, Scheetz T, Assem M, Donovan MD. Microarray determination of the expression of drug transporters in humans and animal species used for the investigation of nasal absorption. Mol Pharm. 2015;12(8):2742–54. https://doi.org/10.1021/acs.molpharmaceut.5b00103.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.George M. The role of organic cation transporters in the nasal uptake and brain distribution of organic cation substrates: University of Iowa; 2013. http://ir.uiowa.edu/cgi/viewcontent.cgi?article=5657&context=etd (use accessed 15 Sept 2017).
- 14.Zidovudine [Internet]. Wishart Research Group. [cited June 25, 2017]. Available from: https://www.drugbank.ca/drugs/DB00495
- 15.Stavudine [Internet]. Wishart Research Group. [cited June 25, 2017]. Available from: https://www.drugbank.ca/drugs/DB0064.
- 16.Koshida R, Cox S, Harmenberg J, Gilljam G, Wahren B. Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1989;33(12):2083–8. https://doi.org/10.1128/AAC.33.12.2083.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Saga TMD, Kawashima H, Araki N, Takahashi JA, Nakashima Y, Higashi T, et al. Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med. 2006;31(12):774–80. https://doi.org/10.1097/01.rlu.0000246820.14892.d2.CrossRefPubMedGoogle Scholar
- 19.Shinomiya A, Miyake K, Okada M, Nakamura T, Kawai N, Kushida Y, et al. 3′-Deoxy-3′-[18F]-fluorothymidine ([18F]-FLT) transport in newly diagnosed glioma: correlation with nucleoside transporter expression, vascularization, and blood–brain barrier permeability. Brain Tumor Pathology. 2013;30(4):215–23. https://doi.org/10.1007/s10014-013-0136-2.CrossRefPubMedGoogle Scholar
- 21.Al-Ghabeish M. Drug transporters in the nasal epithelia and their contributions in drug delivery: University of Iowa; 2013. http://ir.uiowa.edu/cgi/viewcontent.cgi?article=5581&context=etd Google Scholar
- 26.Shingaki T, Katayama Y, Nakaoka T, Irie S, Onoe K, Okauchi T, et al. Visualization of drug translocation in the nasal cavity and pharmacokinetic analysis on nasal drug absorption using positron emission tomography in the rat. Eur J Pharm Biopharm. 2016;99:45–53. https://doi.org/10.1016/j.ejpb.2015.11.014.CrossRefPubMedGoogle Scholar
- 27.Ponto LLB, Walsh SA, Huang J, Mundt C, Thede-Reynolds K, Watkins GL, et al. Pharmacoimaging of blood-brain barrier permeable (FDG) and impermeable (FLT) substrates after intranasal (IN) administration. AAPS J. In review.Google Scholar